North America Intravenous Immunoglobulin Market Size & Outlook
North America intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
North America intravenous immunoglobulin market highlights
- The North America intravenous immunoglobulin market generated a revenue of USD 6,389.6 million in 2024.
- The market is expected to grow at a CAGR of 6.7% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 6,389.6 million |
| Market revenue in 2030 | USD 9,455.8 million |
| Growth rate | 6.7% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, North America region accounted for 46.1% of the global intravenous immunoglobulin market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,201.7 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 20.9% in 2024. Horizon Databook has segmented the North America intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the Intravenous Immunoglobulin (IVIG) market, with a global share of 46.11% in 2024. The North American Intravenous Immunoglobulin (IVIG) market is a leading region, capturing a global market share of 46.11% in 2024. This market is witnessing considerable growth, primarily driven by the increasing demand for IVIG therapies in treating a variety of immunodeficiency diseases and related conditions. The increasing usage of IVIG pharmacies is also contributing to expanding access to medication across the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America intravenous immunoglobulin market size, by country, 2018-2030 (US$M)
North America Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
